Physicians' Academy for Cardiovascular Education

SGLT2i

Concomitant use of diuretics and SGLT2i in HF

10' education - Mar. 23, 2021 - Prof. Patrick Rossignol, MD

Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF

10' education - Feb. 22, 2021 - Carlos Santos-Gallego, MD

SGLT2 inhibitor is kidney protective, even if eGFR <30

3' education - Jan. 26, 2021 - Prof. George Bakris, MD

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

The six pillars of therapy in HFrEF

3' education - Nov. 15, 2020 - Prof. Marc Pfeffer, MD, PhD

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Nephroprotective effects with SGLT2i in CKD patients

3' education - Aug. 30, 2020 - Prof. Hiddo Heerspink, PhD

Remarkably similar findings with another SGLT2i in HFrEF

3' education - Aug. 29, 2020 - Prof. John McMurray

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Prof. Mark Cooper, MD

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

10' education - Sep. 24, 2019 - Prof. Nikolaus Marx, MD

Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes

3' education - Sep. 1, 2019 - Paris, France - Prof. John McMurray

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD - Online CME

The clinical landscape of managing patients with CKD: Where are we now and what can we expect?

10' education - June 14, 2019 - ERA-EDTA 2019 - Will Herrington, MD - Online CME

Importance of protection and prevention in diabetic cardiorenal disease

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. John Deanfield, MD - Online CME

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD - Online CME

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

The future of SGLT2i in HF: Managing patients without T2DM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD

Sustained benefit of SGLT2i in HFrEF by 28 days

Literature - Mar. 31, 2021 - Berg DD, et al. - JAMA Cardiology 2021

Use of dapagliflozin resulted in rapid clinical benefit in HFrEF patients and risk reduction of the primary outcome by dapagliflozin was largest in patients with a more recent HF hospitalization.

Concomitant use of diuretics and SGLT2i in HF

10' education - Mar. 23, 2021 - Prof. Patrick Rossignol, MD
Prof. Rossignol presents results from 2 mechanistic studies and analyses from two large SGLT2i trials in HFrEF patients that provide insights in the management of diuretics with SGLT2i therapy.

Prof. Rossignol presents results from two mechanistic studies and analyses from two large SGLT2i trials in HFrEF patients that provide insights in the management of diuretics with SGLT2i therapy.

Efficacy of two SGLT2i on CV and kidney outcomes in HFrEF according to kidney function

Literature - Feb. 25, 2021 - Jhund PS et al. and Zannad F et al., - Circulation. 2021

Subgroup analyses from DAPA-HF and EMPEROR-Reduced evaluated the effects of dapagliflozin and empagliflozin on CV and kidney outcomes according to baseline kidney function in patients with HFrEF.

Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF

10' education - Feb. 22, 2021 - Carlos Santos-Gallego, MD
What is the mechanism of action resulting in benefit with SGLT2i? Carlos Santos-Gallego discusses the results of the EMPA-TROPISM trial that shows reverse LV remodeling by empagliflozin in non-diabetic HFrEF.

What is the mechanism of action resulting in benefit with SGLT2i? Carlos Santos-Gallego discusses the results of the EMPA-TROPISM trial that shows reverse LV remodeling by empagliflozin in non-diabetic HFrEF.

SGLT2i reduces new-onset T2DM in patients with HFrEF

Literature - Feb. 18, 2021 - Inzucchi SE et al., - Diabetes Care. 2021

This exploratory analysis from DAPA-HF showed that dapagliflozin, compared to placebo, reduced new-onset T2DM in patients with HFrEF without diabetes at baseline.

Proposed new algorithm for sequencing drug treatments for HFrEF

Literature - Feb. 15, 2021 - McMurray JJV and Packer M, - Circulation. 2020
John McMurray and Milton Packer proposed a new algorithm to achieve treatment with a beta-blocker, SGLT2i, ARNI and MRA within 4 weeks in patients with HFrEF.

John McMurray and Milton Packer proposed a new algorithm to achieve treatment with a beta-blocker, SGLT2i, ARNI and MRA within 4 weeks in patients with HFrEF.

Simple biomarker-based risk score for prediction of incident HF in (pre-)diabetes

Literature - Feb. 2, 2021 - Pandey A et al., - JACC Heart Fail. 2020

A risk score based on elevated levels of hs-cTnT, NT-proBNP, and hs-CRP, and presence of left ventricular hypertrophy can stratify incident HF risk in patients with dysglycemia without CVD.

ARNI therapy does not affect CV reduction by SGLT2i in HFrEF

Literature - Feb. 2, 2021 - Packer M et al., - Eur Heart J. 2021

A subanalysis of EMPEROR-Reduced demonstrated that sacubitril/valsartan treatment in patients with HFrEF did not affect risk reducing effects of empagliflozin on HF and kidney events.

SGLT2 inhibitor is kidney protective, even if eGFR <30

3' education - Jan. 26, 2021 - Prof. George Bakris, MD
A post hoc analysis of patients in the CREDENCE trial with baseline eGFR <30 m:/min/1.73 m2 was performed. Prof. Bakris shares the results of this analysis,

A post hoc analysis of patients in the CREDENCE trial with baseline eGFR <30 mL/min/1.73 m² was performed. Prof. Bakris shares the results of this analysis.

2021 Update to the 2017 ACC ECDP for optimization HFrEF treatment

News - Jan. 19, 2021

The ACC Expert Consensus Decision Pathway (ECDP) for optimization of HFrEF treatment provides practical guidance for physicians in managing patients with HFrEF. The 2017 ECDP has now been updated.

SGLT2 inhibitor reduces total burden of CVD in patients with T2DM and ASCVD

Literature - Jan. 7, 2021 - McGuire DK, et al. - Lancet Diabetes Endocrinol 202

A secondary analysis of EMPA-REG OUTCOME demonstrated that empagliflozin reduced total events of CV outcomes and all-cause admission to hospital compared to placebo in patients with T2DM and ASCVD.

NT-proBNP lowering by SGLT2 inhibitor explains small proportion of benefit on HF events

Literature - Dec. 7, 2020 - Januzzi JL Jr, et al. - J Am Coll Cardiol. 2020

A post-hoc analysis of CANVAS showed that the SGLT2 inhibitor canagliflozin reduced NT-proBNP serum levels in T2DM patients. However, this lowering in NT-proBNP only explained 10% of the reduction on hospitalization by HF by canagliflozin.